ArticleDiscover oncology2026
A pathomics-based pyroptosis signature predicts survival in clear cell renal cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Better prognostic tools are needed to improve the clinical management of clear cell renal cell carcinoma (ccRCC). To address this, we developed a novel prognostic model by integrating pathomics features with pyroptosis-related signaling, a strategy not previously explored in ccRCC. Analysis of The Cancer Genome Atlas (TCGA) whole-slide images identified 59 quantitative image features significantly correlated with a pyroptosis gene set. Based on these features, a prognostic risk score was developed using the StepCox[forward]+Lasso algorithm and validated as an independent predictor of patient survival. This model demonstrated robust predictive performance, with time-dependent AUCs of 0.744, 0.729, and 0.716 for 1-, 3-, and 5-year survival and C-indexes of 0.71 and 0.64 in the training and validation sets. This model implicates key pyroptosis-related genes (e.g., GSDMD, GSDME, CASP5, and several CHMP family genes), whose expression links pathological phenotypes to patient outcomes. Single-cell sequencing revealed their specific expression patterns in the ccRCC microenvironment, and functional exploration highlighted GSDMD's potential role. By providing a novel, biologically integrated signature, this model offers a refined tool for prognostic assessment that complements conventional clinical parameters. Ultimately, this pyroptosis-based pathomics model could help guide personalized treatment strategies for ccRCC patients in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.